Smallpox Treatment Market

Smallpox Treatment Market, By Treatment Type (Antiviral Drugs, Vaccination, Supportive Care), By Product Type (Vaccines, Antiviral Drugs), By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), By End User (Healthcare Facilities, Research Institutes Others), And By Region (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Smallpox is an acute contagious disease caused by the variola virus, a member of the orthopoxvirus family. There is no cure for smallpox, but vaccination can be used effectively to prevent infection from developing if given during a period of up to four days after a person has been exposed to the virus. There is no known specific treatment for smallpox, although research is being carried out in an attempt to create a medication capable of killing the virus.

Market Dynamics:

Rise in burden of smallpox, growing demand for safe and effective treatment, rise in focus on the development of safe and effective vaccine, and favorable government initiatives are major factors expected to propel the growth of the global smallpox treatment market.

For instance, in June 2021, the U.S. Food and Drug Administration (FDA) approved Chimerix's brincidofovir (BCV, Tembexa) to treat smallpox. The FDA approved Tembexa under the agency’s Animal Rule, which allows findings from adequate and well-controlled animal efficacy studies to serve as basis of an approval when it is not feasible or ethical to conduct efficacy trials in humans.

Key features of the study:

This report provides in-depth analysis of the global smallpox treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year.

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.

It profiles key players in the global smallpox treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.

Key companies covered as a part of this study include Bavarian Nordic A/S, Nanotherapeutics, Inc., Chimerix, Inc., Pfizer Inc., Merck & Co., Inc., Sanofi Pasteur SA, GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Bavarian Nordic A/S, SIGA Technologies, Inc., Emergent BioSolutions Inc., BioCryst Pharmaceuticals, Inc., Bharat Biotech International Ltd., and Takeda Pharmaceutical Company Limited, among others.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.

The global smallpox treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global smallpox treatment market.

Detailed Segmentation:

Global Smallpox Treatment Market, By Treatment Type:

Antiviral Drugs

Vaccination

Supportive Care

Global Smallpox Treatment Market, By Product Type:

Vaccines

Antiviral Drugs

Global Smallpox Treatment Market, By Distribution Channel:

Hospitals

Clinics

Retail Pharmacies

Online Pharmacies

Global Smallpox Treatment Market, By End User:

Healthcare Facilities

Research Institutes Others

Global Smallpox Treatment Market, By Geography:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Company Profiles:

Bavarian Nordic A/S

Nanotherapeutics, Inc.

Chimerix, Inc.

Pfizer Inc.

Merck & Co., Inc.

Sanofi Pasteur SA

GlaxoSmithKline plc

Novartis International AG

Johnson & Johnson

Bavarian Nordic A/S

SIGA Technologies, Inc.

Emergent BioSolutions Inc.

BioCryst Pharmaceuticals, Inc.

Bharat Biotech International Ltd.

Takeda Pharmaceutical Company Limited
Show more